Adherence and retention of female injection drug users in a phase III clinical trial in inner city Baltimore

  • Richard D. Semba
  • , Erin P. Ricketts
  • , Shruti F. Mehta
  • , Gregory D. Kirk
  • , Carl Latkin
  • , Noya Galai
  • , David Vlahov

Research output: Contribution to journalArticlepeer-review

Abstract

Adherence and retention of female injection drug users (IDUs) in clinical trials are not well known and were evaluated among 458 female IDUs in a clinical trial in Baltimore. Of all, 62.9% were adherent to visits (attended ≥ 80% of visits). Of women with ≥ 1 visit after enrollment, 76% were adherent to treatment (took ≥ 80% of pills); 27.7% were lost to follow-up (missed ≥ 3 consecutive visits). Women nonadherent to visits were younger and less likely to be on methadone. Women lost to follow-up were younger, more often white, not on methadone, and injecting drugs daily. Fair-moderate adherence to visits and treatment occurs among female IDUs in a clinical trial.

Original languageEnglish
Pages (from-to)71-80
Number of pages10
JournalAmerican Journal of Drug and Alcohol Abuse
Volume33
Issue number1
DOIs
StatePublished - Jan 2007

Bibliographical note

Funding Information:
This study was supported by the National Institute on Nursing Research (R01 NR009478) and the National Institute on Drug Abuse (R01 DA15022).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Adherence
  • Clinical trial
  • HCV
  • HIV
  • Injection drug user
  • Minority

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Clinical Psychology
  • Psychiatry and Mental health

Fingerprint

Dive into the research topics of 'Adherence and retention of female injection drug users in a phase III clinical trial in inner city Baltimore'. Together they form a unique fingerprint.

Cite this